Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

he requirements and plans for regulatory filings and approvals for clofarabine in additional indications. These risks and uncertainties include, among others, the timing and results of clinical studies for clofarabine; the timing of discussions with the EMEA and FDA regarding clinical study results and approval of clofarabine in additional indications; the timing and content of decisions by the EMEA and FDA related to clinical trials and approval of clofarabine in additional indications; the actual efficacy and safety of clofarabine for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Evoltra(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.

Media Contact: Investor Contact:

Maria Cantor Patrick Flanigan

(617) 768-6690 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... 31, 2015 LabStyle Innovations Corp. (OTCQB: ... today announced it recently closed a round of ... used to support the global rollout and initial ... cloud-based, diabetes management solution that includes novel software ... glucose monitoring device, and for working capital purposes. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Proove Biosciences, Inc. ... Technology Alliance Annual High Tech Awards. , Now in its 22nd year, this ... which drive innovation here, across the nation and around the world. The OC Tech ...
(Date:8/28/2015)... PA (PRWEB) , ... August 28, 2015 , ... ... Chairman, Chuck Gardner, has organized and will present a session on chemical spectroscopic ... 2. This conference and exposition is Asia’s largest analytical and scientific instruments show ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... tell his fellow travelers a thing or two about commuting. ... as an executive-in-residence and one of its portfolio companies, ... development. , , Gregg Fergus And since Fergus ... nine years, his new posts reduce the distance between home ...
... disappointed by not being able to visit a PEAK 10 ... their services after an executive scheduled a meeting with me. This ... get. Several calls came in within 15 minutes of publication, including ... to say about watching claims made within the data center services ...
... made up only one percent of the venture capital market ... the venture capital pie had grown to 14 percent. The ... produce alternative fuels, keep the air and water clean, and ... may prefer to pick the winners in the cleantech world, ...
Cached Biology Technology:Biotech executive books a career flight that's closer to home 2Biotech executive books a career flight that's closer to home 3Data centers: Buyers beware of over-hyped facilities 2Data centers: Buyers beware of over-hyped facilities 3Data centers: Buyers beware of over-hyped facilities 4Bio-energy and cleantech grab attention of investors 2Bio-energy and cleantech grab attention of investors 3Bio-energy and cleantech grab attention of investors 4
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... year farmers spend a lot of money trying to ... to maize production in the United States and, more ... working on validating a model for estimating damage functions. ... has refined a model developed in 2009 by researchers ...
... ATLANTA Auditory systems differ between sexes in sparrows ... has found. The work adds to our knowledge of ... of humans, are able to change. Megan Gall, ... the peripheral auditory systems of male and female house ...
... Vertebrates, transition to living on land, instead of only in ... Now, researchers reporting in the December issue of the Cell ... the development of hands and feet occurred through the gain ... "First, and foremost, this finding helps us to understand the ...
Cached Biology News:Quantifying corn rootworm damage 2Quantifying corn rootworm damage 3Researcher finds gender differences in seasonal auditory changes 2From fish to man: Research reveals how fins became legs 2
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
Biology Products: